Evidence map›Paper›PMID 29632738›Full record

ArticleOncoimmunology

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission.

Jennifer L Hsu, Christian E Bryant, Michael S Papadimitrious, Benjamin Kong, Robin E Gasiorowski, Daniel Orellana, Helen M McGuire, Barbara Fazekas de St Groth, Douglas E Joshua, P Joy Ho and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Jennifer L HsuDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, Australia.
Christian E BryantDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, Australia.
Michael S PapadimitriousDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, Australia.
Benjamin KongDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, Australia.
Robin E GasiorowskiDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, Australia.
Daniel OrellanaInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Helen M McGuireRamaciotti Facility for Human Systems Biology, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Barbara Fazekas de St GrothRamaciotti Facility for Human Systems Biology, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Douglas E JoshuaInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
P Joy HoInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Stephen LarsenInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Harry J IlandInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
John GibsonInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Georgina J ClarkDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, Australia.
Phillip D FrommDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, Australia.
Derek Nj HartDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, Australia.
The University of Sydney · AURoyal Prince Alfred Hospital · AUAnzac Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Only modest advances in AML therapy have occurred in the past decade and relapse due to residual disease remains the major challenge. The potential of the immune system to address this is evident in the success of allogeneic transplantation, however this leads to considerable morbidity. Dendritic cell (DC) vaccination can generate leukemia-specific autologous immunity with little toxicity. Promising results have been achieved with vaccines developed

Indexed as

Acute Myeloid LeukemiaAllogeneic Haematopoietic Stem Cell TransplantationBlood Dendritic CellCheckpoint InhibitorChemotherapyImmunotherapyT Cell Landscape

Identifiers

PMID29632738
PMCPMC5889209
OpenAlexW2784090956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.